Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial
…, J Horakova, K Reguliova, M Tyblova… - The Lancet …, 2021 - thelancet.com
Background There is an unmet need for treatment options for generalised myasthenia gravis
that are effective, targeted, well tolerated, and can be used in a broad population of patients…
that are effective, targeted, well tolerated, and can be used in a broad population of patients…
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double …
…, J Pitha, I Novakova, M Tyblova, M Wolfova… - The Lancet …, 2017 - thelancet.com
Background Complement is likely to have a role in refractory generalised myasthenia gravis,
but no approved therapies specifically target this system. Results from a phase 2 study …
but no approved therapies specifically target this system. Results from a phase 2 study …
Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial
…, M Tyblova, E Meluzinova, R Ampapa, M Valis… - The Lancet …, 2021 - thelancet.com
Background Tolebrutinib is an oral, CNS-penetrant, irreversible inhibitor of Bruton's tyrosine
kinase, an enzyme expressed in B lymphocytes and myeloid cells including microglia, which …
kinase, an enzyme expressed in B lymphocytes and myeloid cells including microglia, which …
Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score
…, JF Heubach, R Sandbrink, M Tyblova… - The Lancet …, 2009 - thelancet.com
Background Prediction of susceptibility to multiple sclerosis (MS) might have important
clinical applications, either as part of a diagnostic algorithm or as a means to identify high-risk …
clinical applications, either as part of a diagnostic algorithm or as a means to identify high-risk …
Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 …
…, G Matte, S Botez, M Tyblova, M Jakubikova… - The Lancet …, 2023 - thelancet.com
Background Generalised myasthenia gravis is a chronic, unpredictable, and debilitating
autoimmune disease. New treatments for this disease are needed because conventional …
autoimmune disease. New treatments for this disease are needed because conventional …
Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis
…, I Novakova, M Tyblova, I Jurajdova, M Wolfova… - Muscle & …, 2019 - Wiley Online Library
Introduction: Eculizumab is effective and well tolerated in patients with antiacetylcholine
receptor antibody‐positive refractory generalized myasthenia gravis (gMG; REGAIN; …
receptor antibody‐positive refractory generalized myasthenia gravis (gMG; REGAIN; …
Thalamic atrophy is associated with development of clinically definite multiple sclerosis
R Zivadinov, E Havrdová, N Bergsland, M Tyblova… - Radiology, 2013 - pubs.rsna.org
Purpose To investigate the association between the development of thalamic and cortical
atrophy and the conversion to clinically definite multiple sclerosis (CDMS) in patients with …
atrophy and the conversion to clinically definite multiple sclerosis (CDMS) in patients with …
Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event
…, D Badgett, M Tamaño-Blanco, M Tyblova… - Journal of Neurology …, 2013 - jnnp.bmj.com
Objectives To investigate the associations of serum lipid profile with disease progression in
high-risk clinically isolated syndromes (CIS) after the first demyelinating event. Methods High …
high-risk clinically isolated syndromes (CIS) after the first demyelinating event. Methods High …
Predictive factors for a severe course of COVID‐19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival
M Jakubíková, M Týblová, A Tesař… - European Journal of …, 2021 - Wiley Online Library
Background and purpose Myasthenia gravis (MG) patients could be a vulnerable group in the
pandemic era of coronavirus 2019 (COVID‐19) mainly due to respiratory muscle weakness…
pandemic era of coronavirus 2019 (COVID‐19) mainly due to respiratory muscle weakness…
Long‐term safety and efficacy of Eculizumab in Aquaporin‐4 IgG‐positive NMOSD
…, J Pitha, P Nytrova, I Novakova, M Tyblova… - Annals of …, 2021 - Wiley Online Library
Objective During PREVENT (NCT01892345), eculizumab significantly reduced relapse risk
versus placebo in patients with aquaporin‐4 immunoglobulin G‐positive neuromyelitis …
versus placebo in patients with aquaporin‐4 immunoglobulin G‐positive neuromyelitis …